Trial Profile
Retrospective, cohort study comparing bevacizumab against aflibercept in patients with exudative age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Dec 2015
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- 03 Dec 2015 New trial record